Franck Dubin

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mıkhael, Paul G. Richardson, Saad Z. Usmani et al. · Blood · 2019 · 90 citations · Full text

Medicine, Hematology, Oncology +14

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

Cristian Villanueva, Ahmad Awada, Mario Campone et al. · European Journal of Cancer · 2011 · 65 citations

Medicine, Oncology, Pharmacology +17

S824 A PHASE 3 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW‐DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW‐DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · HemaSphere · 2019 · 31 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, Joseph Mıkhael, Saad Z. Usmani et al. · Blood · 2016 · 23 citations

Medicine, Oncology, Pharmacotherapy +16